AR882 is an investigational selective uric acid transporter 1 inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible ...
Bone erosion in patients with gout and tophi was associated with tophi duration, drinking history, ulceration, and serum creatinine levels. Bone erosion in patients with gout and tophi was associated ...
gout of foot The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum uric acid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results